ARS Pharmaceuticals (SPRY) EBITDA

annual EBITDA:

-$3.08M+$64.44M(+95.43%)
December 31, 2024

Summary

  • As of today (June 25, 2025), SPRY annual EBITDA is -$3.08 million, with the most recent change of +$64.44 million (+95.43%) on December 31, 2024.
  • During the last 3 years, SPRY annual EBITDA has risen by +$16.16 million (+83.98%).
  • SPRY annual EBITDA is now -565.87% below its all-time high of -$463.00 thousand, reached on December 1, 2020.

Performance

1-year change

+95.43%

3-year change

+83.98%

5-year change

-565.87%

15-year change

-565.87%

SPRY EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

72.9%
SPRY annual EBITDA is higher than 72.9% of companies in Healthcare sector

Range

All-time high

-$463.00K

3-year low

-$67.52M

Earnings dates

Last annual earnings report date

Dec 31, 2024
SPRY previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
SPRY next annual earnings announcement has not yet been scheduled

OtherSPRYincome statement metrics

Annual revenue

$89.15M
SPRY annual revenue is $89.15 million

annual net income

$8.00M
SPRY annual net profit is $8.00 million

annual EBIT

-$3.08M
SPRY annual earnings before interest & taxes is -$3.08 million

Annual EPS

$0.08
SPRY annual earnings per share is $0.08

quarterly EBITDA:

-$37.18M-$84.37M(-178.77%)
March 31, 2025

Summary

  • As of today (June 25, 2025), SPRY quarterly EBITDA is -$37.18 million, with the most recent change of -$84.37 million (-178.77%) on March 31, 2025.
  • Over the past year, SPRY quarterly EBITDA has dropped by -$23.98 million (-181.81%).
  • SPRY quarterly EBITDA is now -178.77% below its all-time high of $47.20 million, reached on December 31, 2024.

Performance

3-month change

-178.77%

1-year change

-181.81%

3-year change

-427.41%

5-year change

-

SPRY quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

12.5%
SPRY quarterly EBITDA is higher than 12.5% of companies in Healthcare sector

Range

All-time high

$47.20M
SPRY quarterly EBITDA is currently -178.77% below its historical high of $47.20 million

3-year low

-$37.18M
SPRY quarterly EBITDA is currently at its 3-year low

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
SPRY previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 6, 2025
SPRY next earnings announcement is scheduled for Aug 6, 2025

OtherSPRYincome statement metrics

Quarterly revenue

$7.97M
SPRY quarterly revenue is $7.97 million

quarterly net income

-$33.94M
SPRY quarterly net profit is -$33.94 million

quarterly EBIT

-$37.18M
SPRY quarterly earnings before interest & taxes is -$37.18 million

Quarterly EPS

-$0.35
SPRY quarterly earnings per share is -$0.35

TTM EBITDA:

-$27.07M-$23.98M(-777.98%)
March 31, 2025

Summary

  • As of today (June 25, 2025), SPRY TTM EBITDA is -$27.07 million, with the most recent change of -$23.98 million (-777.98%) on March 31, 2025.
  • Over the past year, SPRY TTM EBITDA has increased by +$34.93 million (+56.34%).
  • SPRY TTM EBITDA is now -777.98% below its all-time high of -$3.08 million, reached on December 31, 2024.

Performance

3-month change

-777.98%

1-year change

+56.34%

3-year change

-284%

5-year change

-

SPRY TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

42.52%
SPRY TTM EBITDA is higher than 42.52% of companies in Healthcare sector

Range

All-time high

-$3.08M

3-year low

-$72.44M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
SPRY previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 6, 2025
SPRY next earnings announcement is scheduled for Aug 6, 2025

OtherSPRYincome statement metrics

TTM revenue

$97.12M
SPRY TTM revenue is $97.12 million

TTM net income

-$15.65M
SPRY TTM net profit is -$15.65 million

TTM EBIT

-$27.07M
SPRY TTM earnings before interest & taxes is -$27.07 million

TTM EPS

-$0.17
SPRY TTM earnings per share is -$0.17

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

annual EBITDA

-$3.08M
SPRY annual EBITDA is -$3.08 million

annual net income

$8.00M
SPRY annual net profit is $8.00 million

annual interest expense

-
SPRY annual interest expense value is unknown

annual income tax

$288.00K
SPRY annual income tax is $288.00 thousand

annual D&A

-$7.17M
SPRY annual depreciation & amortization is -$7.17 million

SPRY EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+95.4%-181.8%+56.3%
3 y3 years+84.0%-427.4%-284.0%
5 y5 years-565.9%--

SPRY EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+95.4%-178.8%at low-778.0%+62.6%
5 y5-year-565.9%+95.4%-178.8%at low-778.0%+62.6%
alltimeall time-565.9%+95.4%-178.8%at low-778.0%+62.6%

SPRY EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
-$37.18M(-178.8%)
-$27.07M(+778.0%)
Dec 2024
-$3.08M(-95.4%)
$47.20M(-317.0%)
-$3.08M(-94.9%)
Sep 2024
-
-$21.75M(+41.8%)
-$60.51M(+6.6%)
Jun 2024
-
-$15.34M(+16.3%)
-$56.74M(-8.5%)
Mar 2024
-
-$13.19M(+29.0%)
-$62.00M(-8.2%)
Dec 2023
-$67.52M
-$10.23M(-43.1%)
-$67.52M(-6.8%)
Sep 2023
-
-$17.98M(-12.7%)
-$72.44M(+18.6%)
DateAnnualQuarterlyTTM
Jun 2023
-
-$20.60M(+10.1%)
-$61.08M(+30.5%)
Mar 2023
-
-$18.71M(+23.6%)
-$46.82M(+33.2%)
Dec 2022
-$35.20M(+82.9%)
-$15.14M(+128.7%)
-$35.16M(+75.7%)
Sep 2022
-
-$6.62M(+4.4%)
-$20.02M(+49.5%)
Jun 2022
-
-$6.34M(-10.0%)
-$13.39M(+90.0%)
Mar 2022
-
-$7.05M
-$7.05M
Dec 2021
-$19.24M(+4055.7%)
-
-
Dec 2020
-$463.00K
-
-

FAQ

  • What is ARS Pharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for ARS Pharmaceuticals?
  • What is ARS Pharmaceuticals annual EBITDA year-on-year change?
  • What is ARS Pharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for ARS Pharmaceuticals?
  • What is ARS Pharmaceuticals quarterly EBITDA year-on-year change?
  • What is ARS Pharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for ARS Pharmaceuticals?
  • What is ARS Pharmaceuticals TTM EBITDA year-on-year change?

What is ARS Pharmaceuticals annual EBITDA?

The current annual EBITDA of SPRY is -$3.08M

What is the all time high annual EBITDA for ARS Pharmaceuticals?

ARS Pharmaceuticals all-time high annual EBITDA is -$463.00K

What is ARS Pharmaceuticals annual EBITDA year-on-year change?

Over the past year, SPRY annual EBITDA has changed by +$64.44M (+95.43%)

What is ARS Pharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of SPRY is -$37.18M

What is the all time high quarterly EBITDA for ARS Pharmaceuticals?

ARS Pharmaceuticals all-time high quarterly EBITDA is $47.20M

What is ARS Pharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, SPRY quarterly EBITDA has changed by -$23.98M (-181.81%)

What is ARS Pharmaceuticals TTM EBITDA?

The current TTM EBITDA of SPRY is -$27.07M

What is the all time high TTM EBITDA for ARS Pharmaceuticals?

ARS Pharmaceuticals all-time high TTM EBITDA is -$3.08M

What is ARS Pharmaceuticals TTM EBITDA year-on-year change?

Over the past year, SPRY TTM EBITDA has changed by +$34.93M (+56.34%)
On this page